Open-label extension study following the Late-Onset Treatment Study (LOTS) of alglucosidase alfa (Q42670886)

4 November 2017

title

Open-label extension study following the Late-Onset Treatment Study (LOTS) of alglucosidase alfa (English)

1 reference

4 November 2017

Robert J Hopkin

6

0 references

Ans van der Ploeg

1

object named as

Ans T van der Ploeg

1 reference

4 November 2017

4

Joel Charrow

1 reference

4 November 2017

7

Priya S Kishnani

1 reference

4 November 2017

Richard Barohn

2

1 reference

4 November 2017

Lisa Carlson

3

1 reference

4 November 2017

Paula R Clemens

5

1 reference

4 November 2017

Pascal Laforêt

8

1 reference

4 November 2017

Claire Morgan

9

1 reference

4 November 2017

Sharon Nations

10

1 reference

4 November 2017

Alan Pestronk

11

1 reference

4 November 2017

Horacio Plotkin

12

1 reference

4 November 2017

Barry E Rosenbloom

13

1 reference

4 November 2017

Katherine B Sims

14

1 reference

4 November 2017

Elisa Tsao

15

1 reference

4 November 2017

language of work or name

1 reference

17 September 2012

1 reference

Molecular Genetics and Metabolism

4 November 2017

published in

1 reference

4 November 2017

volume

107

1 reference

4 November 2017

issue

3

1 reference

4 November 2017

page(s)

456-461

1 reference

Course of disability and respiratory function in untreated late-onset Pompe disease

4 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016/J.YMGME.2012.09.015

Late onset Pompe disease: Clinical and neurophysiological spectrum of 38 patients including long-term follow-up in 18 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMGME.2012.09.015

Clinical features of late-onset Pompe disease: a prospective cohort study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMGME.2012.09.015

Rate of disease progression during long-term follow-up of patients with late-onset Pompe disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMGME.2012.09.015

Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMGME.2012.09.015

A randomized study of alglucosidase alfa in late-onset Pompe's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMGME.2012.09.015

Desensitization of an adult patient with Pompe disease and a history of anaphylaxis to alglucosidase alfa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMGME.2012.09.015

Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMGME.2012.09.015

Long-term observational, non-randomized study of enzyme replacement therapy in late-onset glycogenosis type II

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMGME.2012.09.015

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMGME.2012.09.015

Disease severity in children and adults with Pompe disease related to age and disease duration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMGME.2012.09.015

10.1016/J.YMGME.2012.09.015

7 January 2021

Identifiers

DOI

1 reference

4 November 2017

1 reference